Donna Przepiorka

29.0k citations

197 papers · 18.2k indexed · 6 hit papers · h-index 59

Hematology top 0.01%
Immunology top 0.2%
Oncology top 0.2%
Genetics top 0.1%
Public Health, Environmental and Occupational Health top 0.5%

Co-authors: Peyton Martin P Beatty Daniel Weisdorf Jill Hows Klingemann Hg Thomas Ed Richard E. Champlin Sergio Giralt
Topics: Hematopoietic Stem Cell Transplantation (103 papers)Acute Myeloid Leukemia Research (34 papers)Acute Lymphoblastic Leukemia research (23 papers)
Cited by: Hematology Transplantation Genetics
Journals: Nature JAMA Journal of Clinical Oncology
Partner nations: United States France Canada

In The Last Decade

Donna Przepiorka

193 papers receiving 17.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1994 Consensus Conference on Acute GVHD Grading.

1995 4.0k citations Donna Przepiorka et al. PubMed profile →
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

1997 909 citations Paolo Anderlini, Donna Przepiorka et al. profile →
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

1998 738 citations Donna Przepiorka, Paolo Anderlini et al. profile →
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

2018 610 citations Robert Q. Le, Liang Li et al. The Oncologist profile →
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report

2015 280 citations Donna Przepiorka et al. profile →
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

2018 252 citations Aviva C. Krauss, Xin Gao et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Donna Przepiorka

Since Specialization

Citations

This map shows the geographic impact of Donna Przepiorka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Przepiorka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Przepiorka more than expected).

Fields of papers citing papers by Donna Przepiorka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donna Przepiorka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Przepiorka. The network helps show where Donna Przepiorka may publish in the future.

Co-authorship network of co-authors of Donna Przepiorka

This figure shows the co-authorship network connecting the top 25 collaborators of Donna Przepiorka. A scholar is included among the top collaborators of Donna Przepiorka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna Przepiorka. Donna Przepiorka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy 2025 ·Clinical Cancer Research ·Cara A. Rabik,Shu Wang,(unknown),Donna Przepiorka,Jonathon Vallejo,Xiling Jiang,Marc R. Theoret,R. Angelo de Claro	0
2	FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy 2025 ·Clinical Cancer Research ·Robert Q. Le,Kamar Godder,(unknown),(unknown),(unknown),Moran Choe,(unknown),Donna Przepiorka,Jonathon Vallejo,Ankit Shah,(unknown),Brenda J. Gehrke,Willie Wilson,Andrea Siegel,(unknown),(unknown),(unknown),Richard Pazdur,Marc R. Theoret,R. Angelo de Claro	0
3	FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy 2022 ·Clinical Cancer Research ·Emily Y. Jen,Xin Wang,Meng Li,Hongshan Li,Shwu‐Luan Lee,Nina Ni,Donna Przepiorka,Jonathon Vallejo,Rupert W. Leong,Lian Ma,Brenda J. Gehrke,(unknown),Marc R. Theoret,R. Angelo de Claro	14
4	FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation 2021 ·Clinical Cancer Research ·Dianne Pulte,Kelly J. Norsworthy,Yaping Wang,(unknown),Hisham Qosa,Ramadevi Gudi,Donna Przepiorka,Wentao Fu,Ólanrewaju O. Okusanya,Kirsten B. Goldberg,R. Angelo de Claro,Ann T. Farrell,Richard Pazdur	57
5	FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia 2019 ·Clinical Cancer Research ·Kelly J. Norsworthy,Kunthel By,Sriram Subramaniam,Luning Zhuang,Pedro L. Del Valle,Donna Przepiorka,Yuan Li Shen,Christopher M. Sheth,Chao Liu,Rupert W. Leong,Kirsten B. Goldberg,Ann T. Farrell,Richard Pazdur	93
6	FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation 2019 ·Clinical Cancer Research ·Kelly J. Norsworthy,Lola Luo,Vicky Hsu,Ramadevi Gudi,Sarah E. Dorff,Donna Przepiorka,Albert Deisseroth,Yuan Li Shen,Christopher M. Sheth,Rosane Charlab,Gene M. Williams,Kirsten B. Goldberg,Ann T. Farrell,Richard Pazdur	102
7	FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease 2019 ·The Oncologist ·Donna Przepiorka,Lola Luo,Sriram Subramaniam,Junshan Qiu,Ramadevi Gudi,Lea Cunningham,Lei Nie,Rupert W. Leong,Lian Ma,Christopher M. Sheth,Albert Deisseroth,Kirsten B. Goldberg,Gideon M. Blumenthal,Richard Pazdur	91
8	FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm 2019 ·Clinical Cancer Research ·Emily Y. Jen,Xin Gao,Liang Li,Luning Zhuang,Natalie E. Simpson,Baikuntha Aryal,Rong Wang,Donna Przepiorka,Yuan Li Shen,Rupert W. Leong,(unknown),Christopher M. Sheth,(unknown),Kirsten B. Goldberg,Ann T. Farrell,Gideon M. Blumenthal,Richard Pazdur	65
9	FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemiabreakdown → 2018 ·Clinical Cancer Research ·Aviva C. Krauss,Xin Gao,Liang Li,Michael L. Manning,Paresma Patel,Wentao Fu,Kumar G. Janoria,Gerlie Gieser,David A. Bateman,Donna Przepiorka,Yuan Li Shen,Stacy S. Shord,Christopher M. Sheth,Anamitro Banerjee,Jiang Liu,Kirsten B. Goldberg,Ann T. Farrell,Gideon M. Blumenthal,Richard Pazdur	252
10	FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia 2018 ·Clinical Cancer Research ·Maura O’Leary,Xiaobin Lü,Ying Huang,Xue Lin,Iftekhar Mahmood,Donna Przepiorka,Denise Gavin,Shiowjen Lee,Ke Liu,Bindu George,Wilson W. Bryan,Marc R. Theoret,Richard Pazdur	221
11	FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease 2018 ·Clinical Cancer Research ·Emily Y. Jen,(unknown),Aaron J. Schetter,Donna Przepiorka,Yuan Li Shen,Donna Roscoe,Rajeshwari Sridhara,Albert Deisseroth,Reena Philip,Ann T. Farrell,Richard Pazdur	98
12	FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndromebreakdown → 2018 ·The Oncologist ·Robert Q. Le,Liang Li,Weishi Yuan,Stacy S. Shord,Lei Nie,Bahru Habtemariam,Donna Przepiorka,Ann T. Farrell,Richard Pazdur	610
13	FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia 2018 ·The Oncologist ·Kelly J. Norsworthy,Chia‐Wen Ko,Jee Eun Lee,Jiang Liu,Christy S. John,Donna Przepiorka,Ann T. Farrell,Richard Pazdur	189
14	FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia 2018 ·The Oncologist ·Dianne Pulte,Jonathon Vallejo,Donna Przepiorka,Lei Nie,Ann T. Farrell,Kirsten B. Goldberg,Amy E. McKee,Richard Pazdur	44
15	FDA Approval: Blinatumomab 2015 ·Clinical Cancer Research ·Donna Przepiorka,Chia‐Wen Ko,Albert Deisseroth,Carolyn L. Yancey,(unknown),Haw-Jyh Chiu,Brenda J. Gehrke,(unknown),Robert C. Kane,Susan Kirshner,Nitin Mehrotra,Tiffany K. Ricks,Deborah H. Schmiel,Pengfei Song,Ping Zhao,Qing Zhou,Ann T. Farrell,Richard Pazdur	261
16	Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. 2002 ·PubMed ·James L. Murray,(unknown),Donna Przepiorka,(unknown),Nuhad K. Ibrahim,Daniel J. Booser,Gabriel N. Hortobágyi,Andrzej P. Kudelka,Kenneth H. Grabstein,Martin A. Cheever,Constantin G. Ioannides	119
17	Clinical trials of HER-2/neu-specific vaccines. 2000 ·PubMed ·James L. Murray,Donna Przepiorka,(unknown)	28
18	Practical considerations in the use of tacrolimus for allogeneic marrow transplantation 1999 ·Bone Marrow Transplantation ·Donna Przepiorka,(unknown),JW Fay,(unknown),John R. Wingard	45
19	Allogeneic blood stem cell transplantation 1997 ·Martin Körbling,Donna Przepiorka,Paolo Anderlini,Richard E. Champlin	12
20	Rapid Debulking and CD34 Enrichment of Filgrastim-Mobilized Peripheral Blood Stem Cells by Semiautomated Density Gradient Centrifugation in a Closed System 1996 ·Journal of Hematotherapy ·Donna Przepiorka,Peter Van Vlasselaer,(unknown),April Durett,(unknown),(unknown),Frank H. Valone,Richard E. Champlin,Martin Körbling	10

About Donna Przepiorka

Donna Przepiorka is a scholar working on Hematology, Transplantation and Genetics, having authored 197 papers that have together received 18.2k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (103 papers), Acute Myeloid Leukemia Research (34 papers) and Acute Lymphoblastic Leukemia research (23 papers). The work is most often cited by research in Hematology (12.0k citations), Transplantation (1.5k citations) and Genetics (3.0k citations). Donna Przepiorka has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Peyton Martin, P Beatty, Daniel Weisdorf, Jill Hows, Klingemann Hg, Thomas Ed, Richard E. Champlin, Sergio Giralt, Börje S. Andersson and Paolo Anderlini. Their work appears in journals such as Nature, JAMA and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact